Dataset:23074321 Search Result
Clinical information
Table 4. Patients With tk and pol Mutations in Varicella Zoster Virus
　 Patient Characteristics  Days Since Diagnosis Clinical/Treatment Details at Time of Sampling Mutations in tk Gene  Mutations in pol Gene
1 Female, 52 y, CML, MA HSCT,
+403 d, MSD		 0 Pneumonia and generalized cutaneous
VZV, ACV iv 15 d		 None (plasma, swab, BAL)  None
25 Recurrent skin lesions after treatment
cessation, ACV iv with good response		 A176G -> E59G (plasma, swab)  None
51 Second recurrence under ACV iv
treatment, FOS iv, recovery		 N.D.  N.D.
2 Female, 16 y, AML, MA HSCT,
+106 d, haploidentical donor		 0 Zoster of left arm, hand, and shoulder,
ACV iv and vACV		 N.D. N.D.
18 Persistent zoster of the arm, vACV  None (plasma) N.D.
54 Progressive outer retinal necrosis, FOS
iv, loss of vision in affected eye,
recovery		 AddC493 -> stop 194 (aqueous humor)  N.D.
plasma N.D.
3 Male, 9 y, erythropoietic
protoporphyria, OLTx, MA
HSCT, +34 d, haploidentical
donor		 0 Facial zoster, vACV N.D.  N.D.
84 Persistent zoster oticus, ACV iv delA76 -> stop 38 (plasma) N.D.
121 Zoster improved, hepatitis, follow-up
treatment with vACV		 delC493 -> stop 171 (plasma day 121) None
C919T -> stop 307 (plasma day 147),  None
C205T -> stop 69 (plasma day 154)  None
161 Persistent facial zoster, progressive
headache and loss of vision, ACV iv
and FOS iv		 delA76 -> stop 38 (plasma, CSF)  None
None (swab)
179 Loss of vision in both eyes, death due to
organ failure		 delA76 -> stop 38 (CSF) None
4 Loss of vision in both eyes, death due to
organ failure		 0 Zoster n. ophtalmicus, ACV and vACV None (swab) None
26 Persistent skin lesions, keratitis None (swab) None
47 Progressive skin lesions, convulsion,
encephalitis, ACV and FOS		 delAAC658 -> del codon 220 (plasmaday 47),delAAC658 -> del codon 220 (CSF day 57) N.D., none
None (plasma day 57)
115 Convulsions, ACV and FOS, recovery N.D. N.D.
5 Female, 64 y, AML, NMA HSCT,+262 d, MUD 0 Abdominal pain, pneumonia, convulsion,
and generalized cutaneous VZV, ACV iv 10 d		 None (plasma, swab)  None
12 Recurrent skin lesions after treatment,
ACV iv 10 days with rapid response		 None (plasma day 12–17),  None
T209C -> T70I (mixture, plasma day 21) None
24 Follow-up treatment with vACV, recovery C118T -> P40S (plasma day 24) None
None (plasma day 26)
6 Female, 2 y, thalassemia, MA
HSCT, -1 d, MSD		 0 Facial zoster, ACV iv N.D. N.D.
15 Persistent facial zoster and dissemination to pubic region, ACV iv and FOS iv and CDV iv (concomitant adenovirus reactivation) None (swab) None
73 Recurrent skin lesions, FOS iv and CDV topical, recovery None (swab) G2066A -> S689N
　 　 　 　 Plasma N.D. Plasma N.D.
Resistance-conferring mutations are depicted in bold, novel mutations in italics.
Abbreviations: ACV, acyclovir; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; add, addition; BAL, bronchoalveolar lavage; CDV, cidofovir; CML, chronic myeloid leukemia; del, deletion; FOS, foscarnet; HSCT, hematopoietic stem cell transplantation; iv, intravenous; MA, myeloablative conditioning; MSD, matched sibling donor; MUD, matched unrelated donor; N.D., not determined, because of too low a load for resistance analysis or no sample available; NMA, nonmyeloablative conditioning; OLTx, orthotopic liver transplantation; vACV, valacyclovir; VZV, varicella zoster virus.